Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Fintel reports that on February 18, 2025, Barclays downgraded their outlook for Moderna (NasdaqGS:MRNA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 78.68% Upside As of February 18 ...

Barclays downgraded Moderna (NASDAQ:MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of major clinical catalysts, and macroeconomic uncertainties that limit the ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA ...

BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.

Barclays downgraded Moderna (MRNA) to Equal Weight from Overweight with a price target of $45, down from $111, post the Q4 report. The firm ...

A second federal judge paused Trump's order against gender-affirming care for youth. ( AP) Johnson & Johnson aims to have a ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...